Duoning Biotechnology
Suzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A biotech developing next-generation, off-the-shelf cell therapies for cancer and autoimmune diseases.
ImmunologyOncology
Technology Platform
Allogeneic cell therapy platform utilizing gene editing to create universal, off-the-shelf CAR-T and other cell-based products.
Opportunities
Potential to revolutionize cell therapy manufacturing and accessibility with a scalable, universal product.
Risk Factors
Significant scientific risk related to graft rejection, durability of response, and potential for severe toxicity in allogeneic settings.
Competitive Landscape
Part of a competitive global field of companies racing to develop safe and effective off-the-shelf cell therapies.